Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies

Improving Lives Together

Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make the difference in their everyday lives.

Specialty pharmaceutical company

Providing solutions to unmet medical needs.

Shield Therapeutics is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer®

Find out more

Our Products

Feraccru®/Accrufer® – convenient, effective and well tolerated

Feraccru®/Accrufer® is a novel oral product that addresses the needs of patients who cannot tolerate existing oral iron products and offers a clear alternative to IV iron therapy.

Find out more

The content of all investor relations materials contained on this website are deemed to be correct at the time of issue/publication.

Shield CEO Greg Madison talks to Proactive London about his strategy for the company and focus on driving our iron deficiency product Accrufer in the US

Aug 2021 - 12:10
View all Investors Audio & Video